Twist Bioscience Q3 Earnings Call Highlights
Twist Bioscience (NASDAQ:TWST) reported Q3 revenue of about $77.3M in the Americas (+30% YoY), $33.6M in EMEA (+9%), and $7.5M in APAC (+26%). Global supply partner revenue was $12.9M. Gross margin was 52.8%. It raised FY2026 revenue guidance to $456M-$457M and forecast Q4 revenue of $123M-$124M.
How this was made
The 30-second read
Why it matters
Key trading inputs are the raised FY2026 revenue range, the Q4 revenue forecast, gross margin progression, and management’s reiterated expectation of adjusted EBITDA breakeven in Q4, alongside operational metrics from manufacturing cost and turnaround improvements.
Market read
Traders can update models around near-term revenue growth and profitability timing based on the explicit FY2026 and Q4 guidance ranges and the stated path to Q4 adjusted EBITDA breakeven.
What to watch
Operating expense run-rate rose year over year, and adjusted EBITDA remains a loss in Q3, so execution risk remains until Q4 breakeven is demonstrated.
Background
The piece summarizes Twist Bioscience’s Q3 earnings call, including regional revenue, AI-enabled discovery demand commentary, Complex Genes launch execution, margin progress, and updated guidance.
Ticker impact
Twist raised fiscal 2026 revenue guidance to $456 million to $457 million and forecast Q4 revenue of $123 million to $124 million.
Likely positive bias for the next session and into earnings-follow-through, with focus on whether AI-enabled demand and Complex Genes execution sustain the raised outlook.
The article provides specific, time-bound financial guidance (FY26 and Q4), margin progression (52.8% gross margin), and a stated path to adjusted EBITDA breakeven in Q4, which are actionable for positioning.
Market effects
Reinforces investor narrative that synthetic biology DNA synthesis demand is benefiting from AI-enabled discovery workflows and higher-complexity offerings.
No specific regional market shock beyond reported revenue mix by Americas, EMEA, and APAC.
Limited broader macro spillover; primarily company-specific read-through to NGS and synthetic biology supply chains.
Counterpoint
Raised guidance may still be sensitive to customer order timing, and the article does not quantify AI revenue, leaving upside harder to underwrite.
Key entities
- public_companyTwist Bioscience
NASDAQ:TWST synthetic biology company reporting Q3 results and raising FY2026 and Q4 revenue guidance.
- executivePatrick Finn
COO and President cited on manufacturing cost reductions and Complex Genes execution.
- executiveLaponis
Management commentary on customer concentration, AI demand, and margin flow-through.
